ライフサイエンスコーパス: developing

1 Developing a causal physics-based model that ultimately

2 , using dragonfly larvae as biosentinels, by developing a citizen-science network to facilitate biolo

3 iles and drug activity data of PDX tumors in developing a clinically translatable predictive cancer b

4 reveal the underlying neural substrates for developing a cognitively flexible brain during early inf

5 Future work includes developing a consensus around characteristics of success

6 In developing a COVID-19 vaccine, we applied technology pre

7 Developing a cure for HIV is a global priority.

8 This work showcases the possibility of developing a family of transition metal polychalcogenide

9 By developing a general thermodynamic model of CRISPR-Cas b

10 We outline prospects of developing a genuine neurohumanities research program.

11 models of stress, which have been crucial in developing a greater understanding of intergenerational

12 the highest aMED score category, the risk of developing a kidney stone was between 13% and 41% lower

13 The data are instrumental for developing a model for the biological water oxidation cy

14 ome missense variants can be informative for developing a more profound understanding of disease path

15 opilina boulardi, they evolved resistance by developing a more reactive cellular immune response.

16 membrane based on existing structural data, developing a novel algorithm to simulate protein complex

17 or translation and synthesis was followed in developing a novel theoretical interpretation of relativ

18 We have generalized this result by developing a numerical approach to PSC that can be appli

19 These findings are a step towards developing a panel of genetic markers assessing risk of

20 This is achieved by first developing a probabilistic model for the prevalence of v

21 Developing a quick method to evaluate bisulfite conversi

22 ined with hydrogeochemical campaigns allowed developing a reactive transport model capable of reprodu

23 NMR-based analysis of beer samples was sped developing a specific protocol enabling the automatic id

24 represents the first expert-led process for developing a standardized approach for establishing benc

25 nce of CenDNA in centromere specification by developing a system to rapidly remove and reactivate CEN

26 Here, by developing a system-level stochastic model constrained b

27 Developing a thorough understanding of how ectotherm phy

28 this is achieved, clear potential exists for developing a vastly improved mechanistic understanding o

29 surfactant function are at increased risk of developing active tuberculosis.

30 tibodies to SARS-CoV-2 predicted the odds of developing acute respiratory distress syndrome, which in

31 nd screen to identify individuals at risk of developing AD.

32 Tinnitus-related risk on developing AD/PD followingly was determined by the Cox r

33 HSD17B13 differentially affect the risk for developing advanced alcohol-related liver disease.

34 ans, or cells is an important determinant in developing advanced nanobiosensor-based theranostic plat

35 of comorbidities may also affect the risk of developing adverse events with TKIs.

36 nd why some people may be more vulnerable to developing affective disorders, we investigated whether

37 s more susceptible to dry eye (DED) symptoms developing after surgery remains an unmet need.

38 sion of allergic asthma in mice with females developing airway remodelling at a much earlier stage th

39 Genetic associations with the risks for developing alcohol-related cirrhosis and HCC were determ

40 s of SRI were at a significantly higher risk developing allergic sensitization(OR [95% CI] = 2.00 [1.

41 nctional ANG appears to decrease the risk of developing ALS but exacerbate ALS once in progress.

42 tein E (APOE) are known to increase risk for developing Alzheimer's disease, however there is controv

43 APOE epsilon4 gene, those at highest risk of developing Alzheimer's disease.

44 up (with 6 infectious serious adverse events developing among 4 patients [9%]).

45 ctional diversity emphasize the necessity of developing an approach that can fill this space.

46 ive aortic degeneration is a crucial step in developing an effective pharmacologic treatment to preve

47 By developing an experimental setup and analysis tools, we

48 The ultimate goal of developing an integrated molecular classification is to

49 phenotypic data and make recommendations for developing an operationally useful, semantically interop

50 a transcription factor expressed within the developing and adult nervous system where it mostly func

51 show that Tao kinase activity is required in developing and as well as adult stages for maintaining n

52 D-19) requires an evidence-based approach to developing and deploying comprehensive clinician mental

53 ignificantly associated with greater risk of developing and dying from an SPC, compared with the gene

54 pact people on river deltas, particularly in developing and least-developed economies.

55 In spite of the efforts in developing and maintaining accurate variant databases, a

56 In addition to developing and updating susceptibility breakpoints, the

57 During prolonged nutrient restriction, developing animals redistribute vital nutrients to favor

58 tion (HER) in alkaline media is critical for developing anion exchange membrane electrolyzers.

59 tigenicity of vaccine candidates, as well as developing antibody-based therapeutics and diagnostics f

60 r, solutions to the scientific challenges of developing antiicing surfaces remain elusive because of

61 emperament (AT) are at an increased risk for developing anxiety and depression.

62 ted the incidence rates and hazard ratios of developing aortic aneurysm or dissection among first-deg

63 Together, these findings may contribute to developing applications for human tracheal tissue repair

64 ing endoplasmic reticulum (ER) stress in the developing appressorium.

65 ends on making fertile flowers but also upon developing appropriate shoot internodes that optimally a

66 Developing arbors have extensive acentrosomal microtubul

67 ends and possible challenges to this rapidly developing area, with a special focus on the fabrication

68 he proposed framework is a first step toward developing asthma remission as a treatment target and sh

69 d be useful as the key genetic resources for developing biofortified and agronomically superior culti

70 Whether this pathway is active in the developing brain is unknown.

71 ally modulated metabolites to neurons in the developing brain.

72 umulates millions of progenitor cells in the developing brain.

73 nings limit our understanding of the child's developing brain.

74 igration time and the increasing size of the developing brain.

75 ting the mitotic surveillance pathway in the developing brain.

76 stem cell (iPSC)-derived neurons that model developing brains, we identified thousands of genetic va

77 Postmenopausal women at increased risk of developing breast cancer were recruited and were randoml

78 mor syndrome (PHTS) and are at high risk for developing breast, thyroid and other cancers and/or auto

79 lial depletion reduces the odor responses of developing, but not preexisting GCs in vivo in both awak

80 heumatoid arthritis (RA) are at high risk of developing cardiovascular disease (CVD).

81 ugh extensive efforts have been dedicated to developing catalysts for hydroamination, the vast majori

82 number of them involve the production by the developing cell of an inhibitory morphogen, but how this

83 ily, is abundantly expressed in cells of the developing cerebral cortex, including neural progenitor

84 This study provides a framework for developing characterization factors for functional diver

85 hildren and adults with ASD and 96 typically developing children and adults, rigorously evaluating ef

86 o optimize cognitive and emotional health in developing children.

87 with ASD versus <1% in mothers of typically developing children.

88 y help identify individuals most at risk for developing chronic PTSD in the aftermath of trauma.

89 We generated homogeneous populations of developing cINs from 15 healthy control (HC) iPSC lines

90 wed a 50% (range, 20-100%) increased risk of developing CL (OR, 1.5; 95% CI, 1.2-2.0; P = .0004).

91 hepatology providers about PC principles and developing clear prognostic criteria for when and how to

92 ] [95% confidence interval]) associated with developing clinical outcomes were: prior hepatic decompe

93 he mind's structure requires more efforts in developing cognitive architectures.

94 and to identify individuals at high risk of developing cognitive impairment.

95 Statistically significant risk factors for developing colon pathology include tobacco use (odds rat

96 There is increasing interest in developing complement regulatory and inhibitory agents t

97 This review explores the developing, complex, and under-recognized role of engine

98 SB ACE2 was reduced in patients subsequently developing complicated disease.

99 r empirical work is warranted with a view to developing comprehensive Fatigue Risk Management Systems

100 s with elevated PRS have an elevated risk of developing contralateral breast cancer, and that the PRS

101 ge cohort of children with ASD and typically developing control children.

102 ing from the apical to the basal side of the developing cortex.

103 cessible records are sparse, especially from developing countries, and are frequently inaccurate thro

104 That these effects are confined to developing countries, which are often dominated by small

105 ly for local laboratories or laboratories in developing countries.

106 tion but the disease is still a challenge in developing countries.

107 s 1290 (758-3719); P < 0.001 and in patients developing CPC vs no-CPC (area under the curve), median

108 the MT, which can increase a woman's risk of developing CVD postmenopausally.

109 (TREM2) are linked with an enhanced risk of developing dementias.

110 ding performance suggest great potentials in developing dental restoration with extended service life

111 stematically identify individuals at risk of developing disease comorbidities.

112 is finding should be taken into account when developing drugs that modulate BAX activity.

113 n between cancer survivor status and risk of developing each comorbidity.

114 weeks' gestation predict the overall risk of developing early preeclampsia and indicate distinct subt

115 dity and mortality associated with COVID-19, developing effective and safe vaccines is a top research

116 Developing effective countermeasures for drowsy driving

117 the drivers of this bottleneck is crucial to developing effective infection control strategies.

118 Developing effective strategies to prevent or treat coro

119 adaptability and poses a major challenge for developing effective strategies to reduce the disease bu

120 Developing effective therapies to reduce morbidity and m

121 anisms responsible for fibrotic diseases and developing effective therapies.

122 ving from the neural crest migrate along the developing embryo and traverse the dermis to reach the e

123 senchymal transition and migrate through the developing embryo to give rise to portions of the outflo

124 effects on the cardiovascular system in the developing embryo, which are independent of effects on t

125 and large field of view imaging of neurons, developing embryos, and centimeter-scale tissue sections

126 Within developing embryos, tissues flow and reorganize dramatic

127 ellation of viral factors that contribute to developing enteric disease remains elusive.

128 improving seasonal influenza vaccines while developing entirely new vaccine platforms.

129 otein expressed mainly in hepatocytes and in developing erythroid cells and is an important focal poi

130 rly, RNAi-mediated knockdown of Tom70 in the developing eye causes roughening and synaptic transmissi

131 e in vivo model, the Drosophila melanogaster developing eye.

132 cy delivers PUFAs from maternal liver to the developing fetus.

133 cts human placentas, inducing defects in the developing fetus.

134 Finally, the developing field of engineered macrophages, including ge

135 curs during a relatively short period within developing flowers.

136 eriment that identified ANT binding sites in developing flowers.

137 ith retinoblastoma are at risk of pineal TRb developing for a shorter period than previously assumed,

138 In the business domain, many initiatives are developing frameworks to assess impacts on biodiversity.

139 Developing future high performance adhesives is predicat

140 genetic predisposition increase the risk of developing GERD.

141 e unfolded protein response and expressed in developing germinal center B cells, can induce Kaposi's

142 d serum bile acids, are at increased risk of developing gestational diabetes mellitus and have impair

143 cancer survivors), and at increased risk of developing grade 3-5 cardiac (4.3 [3.5-5.4] and 5.6 [4.5

144 The developing heart begins as a seemingly straight tube, bu

145 hicken embryo to study the physiology of the developing heart.

146 e proof of principle for a novel strategy in developing highly selective and broad-spectrum antiviral

147 fect synapse formation and maturation in the developing hippocampus.

148 th intermittent acute symptoms indicative of developing HP, 27 with no symptoms and 10 healthy subjec

149 y reveals the existence of mosaic SVs in the developing human brain, likely arising from cell prolife

150 minal zones, reminiscent of processes in the developing human cerebral cortex necessary for generatin

151 ensional cultures that model features of the developing human cerebral cortex(1,2).

152 itro and provides a single-cell atlas of the developing human lung.

153 ates the postmitotic differentiation rate of developing human neurons and disrupting this process imp

154 C magnetic resonance spectroscopy (MRS) is a developing imaging technique that enables non-invasive m

155 ist colonization by pathogens, and train the developing immune system.(1)(,)(2) However, humans are u

156 ed the effect of oil and hypoxia exposure on developing immune systems.

157 r elucidating fundamental biology as well as developing improved diagnostic and theranostic systems.

158 Developing improved vaccines that elicit broader immunit

159 th percentile showed a 57% increased risk of developing incident heart failure compared to a subject

160 features; this highlights the importance of developing individualized approaches to reduce the hypox

161 Cancer patients are at a higher risk for developing influenza (flu)- related complications.

162 Developing insight into tissue-specific transcriptional

163 Studies in developing IONPs as T(1) contrast agents have generated

164 While still in their relative infancy, these developing iPSC-based technologies hold considerable pro

165 o = 2.17; 95% CI 1.14-4.13) and with risk of developing laryngeal granulation tissue (p = 0.02).

166 normal hearing at birth, but are at risk of developing late-onset SNHL.

167 e recent research effort has been devoted to developing lead-free halide perovskite (LFHP) NCs.

168 e models on patient-reported outcomes and on developing less resource-intensive integrated care model

169 his work points out a promising approach for developing Li||LCO batteries for practical applications.

170 Focusing on the developing limb, single-cell RNA data identified 25 cand

171 ish demonstrated nuclear ESR activity in the developing liver.

172 t is about time to investigate clocks in the developing lung.

173 role and challenges of the private sector in developing malaria control programs, which can include e

174 how that Sox10 has multiple functions in the developing mammary gland.

175 This vision can be supported by developing mechanisms to credit utilities for wider oppo

176 We find that contemporaneously developing memory and GC B cells differ in their affinit

177 ds than by candidate genes, are essential to developing methods that may predict the probability of D

178 tritional supplementation interacts with the developing microbiome of the small intestine, the major

179 ide a perspective on the promises of ENS for developing molecular assemblies/processes for functions.

180 ction, significant progress has been made in developing molecular complexes that reduce N(2) into its

181 These studies lay a foundation for developing more advanced dual Mcl-1/Bfl-1 inhibitors tha

182 e endogenous opioid system that will help in developing more effective treatments for pain and addict

183 state and accessibility of chromatin in the developing mouse fetus.

184 find that, in colorectal cancer cells and in developing mouse forelimbs, BCL9 proteins sustain the ac

185 we disrupt minor spliceosome function in the developing mouse limb by ablating one of its essential c

186 delamination of daughter neuroblasts in the developing mouse neocortex.

187 ing human pluripotent stem cells (hPSCs) and developing mouse neurons offers a powerful approach to c

188 even larger dataset consisting of ~2 million developing mouse organ cells, we show Hopper's even repr

189 raction can potentially reduce the chance of developing MRONJ-like lesion in rats.

190 This study highlights the utility of developing multiple GRNs within a species to detect puta

191 logic gates have been extensively applied in developing multiplex processing platforms to provide an

192 Risk of developing myelodysplastic syndrome (MDS) is significant

193 hich accounts for both the absolute reliance developing myofibers have on nuclear accrual to establis

194 elevant research contributing to efforts for developing nanopore methods associated with DNA nanotech

195 tion-dependent effects of antibiotics on the developing neonatal gut microbiota needs to be precisely

196 In a developing nervous system, endogenous electric field (EF

197 number variants (CNVs) have a higher risk of developing neurodevelopmental disorders.

198 se development and presynaptic function in a developing neuronal circuit in its native environment is

199 ortex, including neural progenitor cells and developing neurons.

200 the last decades, great effort has gone into developing new biosensor technologies for applications i

201 pai-conjugated scaffolds is of interest when developing new conducting or electrochromic materials as

202 ts established processes for discovering and developing new medicines.

203 framework for decision making by researchers developing new models.

204 the use of existing tools rather than simply developing new ones.

205 technical and conceptual considerations for developing new safer and more effective anterograde tran

206 eficit > 20%, multivariable-adjusted odds of developing new significant AKI and MAKE increased by 1.2

207 fective application of signaling kinetics to developing new therapeutics requires reliable kinetic as

208 erential vulnerability may provide a key for developing new treatments for PD.

209 g pain and itch holds enormous potential for developing new treatments.

210 ross sectional Cohort (CSC, n=446): patients developing new-onset renal function deterioration 7.7 +/

211 Our studies thus provide a rationale for developing NK cell-based therapies to effectively treat

212 bohydrate profiles with the transcriptome of developing nodules revealed highly activated glycolysis,

213 t regulate T cell quiescence will be key for developing novel approaches to modulate protective and p

214 P-H activation step, and recent progress in developing novel catalytic transformations involving P-C

215 w insight into the sequence requirements for developing novel CPPs for transcellular delivery of carg

216 urn out to be of immense consequence towards developing novel point-of-care hematological analyzers f

217 becoming an increasingly important asset in developing novel therapies for cancer.

218 sease onset and progression is essential for developing novel therapies.

219 tion efforts around the world are focused on developing novel wearable electrochemical biosensors tha

220 white adipose tissue and protects mice from developing obesity and insulin resistance.

221 te in which there is partial positive charge developing on the C-O carbon atom progressing C-H abstra

222 ical setting further underlines the need for developing other technologies, such as phage therapy.

223 utative target loci, including Fgf18, in the developing palatal tissues was verified by ChIP-polymera

224 Risk factors for developing pancreatic cancer include family history, obe

225 pe without functional CWC15, suggesting that developing pollen might be more tolerant to CWC15-mediat

226 ity for the detection of patients at risk of developing post-traumatic stress disorder symptoms.

227 y one patient had a severe adverse reaction, developing posttreatment liver failure resulting in deat

228 f DNA and is actively used as a scaffold for developing potential anticancer and antibiotic agents.

229 to reduce the burden of mental disorders by developing precision medicine approaches globally.

230 onomous mechanisms alone, but also depend on developing premotor circuits.

231 Our findings reveal the challenges of developing prognostic biomarkers for patients with IBD a

232 tients with periodontitis had higher risk of developing prostatitis than patients without periodontit

233 to a traumatic event are at greater risk for developing PTSD; highlighting that sleep potentially pla

234 performed in utero electroporation into the developing rat brain to interfere with Nesprin-2 functio

235 Our aim was to make progress toward developing rational frameworks for selecting electrode m

236 Developing reactions to generate complex and modular bui

237 or years with some plants of 'Emerald' never developing red ringspot symptoms.

238 der adults, stratified by industrialized and developing regions, using data from a systematic review

239 se seasonal synchronization is essential for developing reliable outbreak forecasts and informing sta

240 peel) between 2008 and 2016, and the risk of developing retinal detachment within 1 year of the index

241 tion also prevented the attrition of RGCs in developing retinal organoid cultures without compromisin

242 We determined that, in the developing rodent cerebellar cortex (of both sexes), the

243 Identifying new drug targets and developing safe and effective drugs is both challenging

244 Here we combined loss of Nf1 in developing Schwann cells with global Ink4a/Arf loss and

245 equencies of sound.SIGNIFICANCE STATEMENT In developing sensory systems, groups of neurons that will

246 ancer survivors were both at greater risk of developing severe and disabling, life-threatening, or fa

247 e the dominant symptoms with 15% of patients developing severe illness especially in the elderly and

248 uiring Coronavirus disease-19 (COVID-19) and developing severe outcomes, but current data are conflic

249 y, TICAM2 deficient mice were protected from developing severe systemic inflammation and multi-organ

250 stimated 1-year mortality in each condition, developing simple models (and a tool for calculation) of

251 d by MED12, but also offer a path forward in developing small molecules that target CDK8 in its MED12

252 Therefore, there is significant interest in developing small-molecule receptors that can bind select

253 ptome complexity and proteome specificity in developing soybean nodules.

254 ucosal microbes evolved closest to the host, developing specialized local communities.

255 In the developing spinal cord, Onecut transcription factors con

256 neous activity, which is a characteristic of developing spinal networks operating in a low excitabili

257 tation, altering osteoblast migration to the developing spine, and increasing sensitivity to somitoge

258 allergic patients have an increased odds of developing SSI in comparison to NBL allergic patients.

259 ionated regimens during radiotherapy and for developing strategies to alleviate radiotherapy-induced

260 f this mechanism may provide information for developing strategies to reduce infertility-causing path

261 rgets for human therapeutic intervention and developing stress-resilient crops.

262 e still major issues to be dealt with before developing such systems becomes a commonplace engineerin

263 ich posits that to integrate the senses, the developing system must first be calibrated.

264 This information could assist in developing targeted screenings and health interventions.

265 R218Q knockin podocytes opens an avenue for developing targeted therapy for INF2-mediated FSGS.

266 adults with ASD and 29 age-matched typically developing (TD) individuals.

267 80 and 17 age- and IQ-matched male typically developing (TD) young adults 18-25 years old.

268 stand the heterogeneity of HbF activation by developing techniques to purify and profile differentiat

269 Rapidly developing technologies have recently fueled an exciting

270 Scientists and researchers are developing tests for the rapid detection of individuals

271 RNA secondary structure in miRNA cleavage by developing the new CAP-STRUCTURE-seq method to capture t

272 justed relative risk for women versus men of developing the outcomes of mortality and heart failure r

273 By developing the PlaToLoCo meta-server, we provide the com

274 s can make use of GeNN GPU acceleration when developing their models in Brian, without requiring any

275 eity among human tumors poses a challenge to developing therapies that exploit metabolic vulnerabilit

276 ore numerous and complex lymphatic sprouting developing thereafter.

277 We theorize that the mechanisms involved in developing these cells could be mediated, in part, throu

278 By developing this approach, the functionalities that have

279 In developing this tool, we integrated the transcript datas

280 d for many common challenges associated with developing this type of therapeutic agent.

281 or (TCR) signal transduction is required for developing thymocytes to differentiate from CD4(-)CD8(-)

282 T-ALLs and in distinct populations of normal developing thymocytes, GCs paradoxically induced their o

283 We previously addressed this challenge by developing time-shifted mean-segmented Q (tsMSQ) analysi

284 These observations could be applied in developing tough, impact- and crush-resistant materials

285 story of retinoblastoma and scleral buckling developing tractional RD.

286 nutrient deprivation and the information for developing treatment strategies for disc degeneration.

287 aptic levels might provide new platforms for developing treatments for AS and various forms of autism

288 A fundamental challenge in developing treatments for autism spectrum disorders is t

289 are no contemporary estimates of the risk of developing tuberculosis in exposed children.

290 otential was not associated with the risk of developing UC (P(trend) = .62).

291 However, developing useful mathematical models is challenging bec

292 B cell memory, we have not yet succeeded in developing vaccines for some of the world's most deadly

293 from a subset of commissural neurons in the developing ventral nerve cord produces defasciculated ax

294 Eyes with scleritis have a greater risk of developing vision-threatening corneal complications and

295 However, in the developing visual system, RGC interactions extend beyond

296 g diagnostic groups were compared: typically developing youths (N=693) and youths with DBDs (N=995),

297 regional activation compared with typically developing youths.

298 cell stage, FRET nanoprobes can be imaged in developing zebrafish embryos over seven days with toxici

299 of discrete epicardial subpopulations in the developing zebrafish heart.

300 fects of KIF3B mutant mRNA expression in the developing zebrafish retina.